Early Access

10-QPeriod: Q2 FY2016

Cencora, Inc. Quarterly Report for Q2 Ended Mar 31, 2016

Filed May 5, 2016For Securities:COR

Summary

AmerisourceBergen Corporation (COR) reported a solid first quarter of fiscal year 2016, demonstrating strong revenue growth and a significant shift from net loss to net income. Total revenue increased by 9.3% year-over-year for both the three and six-month periods, driven by the Pharmaceutical Distribution segment and the "Other" segment, bolstered by recent acquisitions like MWI and PharMEDium. This top-line growth, combined with favorable changes in LIFO expense and a significant positive adjustment related to Warrants, propelled the company to a net income of $604.1 million for the quarter, a stark contrast to the net loss reported in the prior year. Investors will be interested in the company's continued strategic acquisitions, its robust revenue generation, and the positive impact of the Warrants adjustment on net income. While operational expenses, particularly distribution, selling, and administrative costs, increased due to acquisitions, the overall financial performance indicates a healthy recovery and growth trajectory. The company's liquidity remains strong, supported by significant credit facilities and operating cash flows, enabling continued investment in growth initiatives and shareholder returns.

Financial Statements
Beta

Key Highlights

  • 1Total revenue increased by 9.3% year-over-year for both the three and six-month periods, reaching $35.7 billion and $72.4 billion, respectively, primarily driven by growth in the Pharmaceutical Distribution and Other segments.
  • 2The company reported a net income of $604.1 million for the quarter ended March 31, 2016, a significant improvement from a net loss of $513.4 million in the prior year period.
  • 3Gross profit saw a substantial increase of 17.9% and 22.6% for the quarter and six-month periods, respectively, largely due to the inclusion of MWI and a decrease in LIFO expense.
  • 4Distribution, selling, and administrative expenses increased by 18.2% and 22.4% due to recent acquisitions (MWI and PharMEDium) and investments to support revenue growth.
  • 5A significant positive impact on operating expenses came from the 'Warrants' item, which showed a gain of $503.9 million in the current quarter compared to an expense of $752.7 million in the prior year quarter, largely due to a decline in the company's stock price.
  • 6Total segment operating income increased by 7.2% and 8.0% year-over-year for the quarter and six-month periods, respectively, driven by acquisitions and revenue growth.
  • 7AmerisourceBergen's liquidity position remains strong with approximately $2.5 billion in cash and cash equivalents and significant availability under its credit facilities.

Frequently Asked Questions